29 participants
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2020-12-17
- Start Date:
- 2016-12-16
- Completion:
- 2019-12-02
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
- BIOLOGICAL
- OTHER
- DRUG